Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvianolate injection in patients undergoing coronary angiography or percutaneous coronary intervention
ChiCTR-IPR-15005998Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of salvianolate in coronary arteriosclerosis (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: Incidence of myocardial injury after coronary artery intervention and Incidence of contrast-induced nephropathy. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
salvianolate
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR-IPR-15005998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15005998.